Pozniak A - Search Results

1

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.

Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Among authors: pozniak a. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.

2

The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.

Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F. Moyle G, et al. Among authors: pozniak a. J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):128-37. doi: 10.1097/00126334-200002010-00004. J Acquir Immune Defic Syndr. 2000. PMID: 10737427 Clinical Trial.

3

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Boffito M, et al. Among authors: pozniak al. AIDS. 2004 Jun 18;18(9):1291-7. doi: 10.1097/00002030-200406180-00007. AIDS. 2004. PMID: 15362661

4

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T; POWER 1 study group. Katlama C, et al. Among authors: pozniak a. AIDS. 2007 Feb 19;21(4):395-402. doi: 10.1097/QAD.0b013e328013d9d7. AIDS. 2007. PMID: 17301557 Clinical Trial.

5

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. Clumeck N, et al. Among authors: pozniak a. HIV Med. 2008 Feb;9(2):65-71. doi: 10.1111/j.1468-1293.2007.00533.x. HIV Med. 2008. PMID: 18257769 Free article.

6

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G. Boffito M, et al. Among authors: pozniak a. Antivir Ther. 2008;13(7):901-7. Antivir Ther. 2008. PMID: 19043924 Clinical Trial.

7

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L. Dickinson L, et al. Among authors: pozniak a. J Antimicrob Chemother. 2009 Jun;63(6):1233-43. doi: 10.1093/jac/dkp102. Epub 2009 Mar 28. J Antimicrob Chemother. 2009. PMID: 19329800 Free PMC article.

8

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance. Geretti AM, et al. Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502. Clin Infect Dis. 2009. PMID: 19331585

9

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. UK Collaborative Group on HIV Drug Resistance, et al. Clin Infect Dis. 2010 May 1;50(9):1275-85. doi: 10.1086/651684. Clin Infect Dis. 2010. PMID: 20353366

10

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

552 results

Search Page